Clin Infect Dis. 2011 May;52(10):1241-7.

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

Source

Pfizer Vaccines, Collegeville, Pennsylvania, USA. peter.paradiso@pfizer.com

Abstract

A 13-valent pneumococcal conjugate vaccine (PCV13), developed with the same chemistry used for the 7-valent PCV vaccine (PCV7) and with the goal of expanding serotype coverage, was clinically evaluated in the United States and Europe and found to induce capsular-specific antibody responses comparable to those of PCV7 for the common serotypes, with robust responses to the 6 additional serotypes. In addition, PCV13 has a similar safety profile to PCV7 and can be given routinely to infants and children, ideally as a 3-dose primary series in the first year of life, with a booster dose in the second year. Children who have initiated their vaccination program with PCV7 can transition to PCV13 at any point in the schedule. Children aged ≥15 months who have been completely vaccinated with PCV7 can receive a single dose of PCV13 to induce immunity to the 6 additional serotypes.

PMID:: 21507921; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Pneumococcal Infections - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). [MMWR Recomm Rep. 2010]
Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep. 2010 Dec 10; 59(RR-11):1-18.
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. [Clin Vaccine Immunol. 2010]
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, Jones TR, Ferrera G, Maida A, Bona G, Sabatini C, et al. Clin Vaccine Immunol. 2010 Jun; 17(6):1017-26. Epub 2010 Apr 28.
Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011. [MMWR Morb Mortal Wkly Rep. 2011]
Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011 Nov 4; 60(43):1477-81.
Review Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®]. [Drugs. 2010]
Review Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].
Duggan ST. Drugs. 2010 Oct 22; 70(15):1973-86.
Review 13-valent pneumococcal conjugate vaccine (PCV13). [Hum Vaccin. 2011]
Review 13-valent pneumococcal conjugate vaccine (PCV13).
Jefferies JM, Macdonald E, Faust SN, Clarke SC. Hum Vaccin. 2011 Oct; 7(10):1012-8. Epub 2011 Oct 1.

See reviews... See all...

Cited by 1 PubMed Central article

Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring. [PLoS One. 2011]
Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring.
Kono M, Hotomi M, Hollingshead SK, Briles DE, Yamanaka N. PLoS One. 2011; 6(10):e27102. Epub 2011 Oct 31.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate va...
Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
Clin Infect Dis. 2011 May ;52(10):1241-7.

PubMed
[Effect of acute or chronic administration of caffeine on performance and on cat...
[Effect of acute or chronic administration of caffeine on performance and on catecholamines during maximal cycle ergometer exercise].
C R Seances Soc Biol Fil. 1990 ;184(1):87-92.

PubMed
Pharmacists' participation in the development of an experiential program.
Pharmacists' participation in the development of an experiential program.
J Pharm Pract. 2010 Aug ;23(4):371-3. Epub 2010 Jun 8 .

PubMed
Long-term potentiation in rat hippocampus is inhibited by low concentrations of ...
Long-term potentiation in rat hippocampus is inhibited by low concentrations of ethanol.
Brain Res. 1990 Dec 24 ;537(1-2):203-8.

PubMed
Stature and robusticity during the agricultural transition: evidence from the bi...
Stature and robusticity during the agricultural transition: evidence from the bioarchaeological record.
Econ Hum Biol. 2011 Jul ;9(3):284-301. Epub 2011 Apr 1 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: